HANG SENG BANK(00011)

Search documents
恒生银行(00011) - 翌日披露报表

2025-08-15 10:26
FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別: 股票 狀態: 新提交 公司名稱: 恒生銀行有限公司 呈交日期: 2025年8月15日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司(「香港聯交所」)證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露,必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 00011 | 說明 | 股份 | | | | | | | 多櫃檯證券代號 | 80011 | RMB 說明 | 股份 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 事件 | | 已發行股份( ...


8月14日港股回购一览





Zheng Quan Shi Bao Wang· 2025-08-15 01:52
Summary of Key Points Core Viewpoint - On August 14, 10 Hong Kong-listed companies conducted share buybacks totaling 4.44 million shares and an amount of 46.21 million HKD, indicating a trend of companies returning capital to shareholders through buybacks [1][2]. Group 1: Buyback Details - Hang Seng Bank repurchased 200,000 shares for 22.87 million HKD, with a highest price of 115.40 HKD and a lowest price of 113.60 HKD, accumulating a total buyback amount of 228 million HKD for the year [1][2]. - MGM China repurchased 1 million shares for 16.18 million HKD, with a highest price of 16.25 HKD and a lowest price of 16.10 HKD, totaling 103 million HKD in buybacks for the year [1][2]. - FIH Mobile (富智康集团) repurchased 208,000 shares for 3.11 million HKD, with a highest price of 15.02 HKD and a lowest price of 14.91 HKD, accumulating 37.53 million HKD in buybacks for the year [1][2]. Group 2: Notable Buyback Activities - The largest buyback amount on August 14 was by Hang Seng Bank at 22.87 million HKD, followed by MGM China at 16.18 million HKD [1][2]. - In terms of share quantity, the highest number of shares repurchased was by I.T Limited (互太纺织) with 2 million shares, followed by MGM China and HYPEBEAST with 1 million and 935,200 shares respectively [1][2]. - I.T Limited's buyback on this date marked its first buyback of the year, while Hang Seng Bank has conducted multiple buybacks totaling 228 million HKD for the year [2].

港股股票回购一览:10只个股获公司回购
Mei Ri Jing Ji Xin Wen· 2025-08-15 01:15
每经AI快讯,数据显示,8月14日,共10只港股获公司回购,2只个股回购金额超千万港元。其中,恒 生银行、美高梅中国、富智康集团回购金额最大,分别获公司回购2286.7万港元、1618.07万港元、 311.04万港元。截至8月14日,今年已有218只港股获公司回购,43只个股年内累计回购金额超亿港元。 其中,腾讯控股、汇丰控股、友邦保险年内累计回购金额最大,分别获公司回购400.43亿港元、222.01 亿港元、176.93亿港元。 ...
智通港股回购统计|8月15日





智通财经网· 2025-08-15 01:11
Group 1 - The article reports on share buybacks conducted by several companies on August 14, 2025, with Hang Seng Bank having the largest buyback amount of 22.867 million HKD for 200,000 shares [1][2] - The total number of shares repurchased by each company varies, with MGM China repurchasing 1,000,000 shares for 16.1807 million HKD, and FIH Mobile repurchasing 208,000 shares for 3.1104 million HKD [2] - The cumulative buyback amounts for the year show that Hang Seng Bank has repurchased a total of 2 million shares, representing 0.106% of its total share capital [2] Group 2 - The buyback activity indicates a trend among companies to return capital to shareholders, with notable participation from firms like HYPEBEAST and North Forest Holdings, which repurchased 935,200 and 9,600 shares respectively [2] - The buyback amounts and percentages of total share capital for other companies include FIH Mobile at 0.401%, and Yanzheng Technology at 1.082%, indicating varying levels of commitment to share repurchase programs [2] - The data reflects a broader strategy among these companies to enhance shareholder value through share buybacks, which can signal confidence in their financial health [1][2]

格隆汇公告精选(港股)︱荣昌生物(09995.HK):泰它西普(商品名:泰爱®)治疗原发性乾燥综合征中国III期临床研究达到主要终点
Ge Long Hui· 2025-08-14 14:59
Group 1: Core Insights - Rongchang Biologics (09995.HK) announced that its innovative drug Taitasip (brand name: Tai Ai®) for treating primary Sjögren's syndrome has met the primary endpoint in a Phase III clinical trial in China [1] - Taitasip is the first BLyS/APRIL dual-target fusion protein drug to complete Phase III research in the field of Sjögren's syndrome globally [1] - The clinical trial was a multi-center, randomized, double-blind, placebo-controlled study aimed at evaluating the efficacy and safety of Taitasip, with the primary endpoint being the change in ESSDAI score at week 24 compared to baseline [1] Group 2: Disease Background and Drug Mechanism - Sjögren's syndrome is a chronic inflammatory autoimmune disease characterized by lymphocytic infiltration and damage to exocrine glands, leading to persistent dry mouth and dry eyes, and can affect multiple organ systems [2] - The prevalence of Sjögren's syndrome in China is estimated to be between 0.3% and 0.7%, with an increasing trend indicating a significant unmet clinical need [2] - Taitasip is a novel dual-target fusion protein developed by the company that simultaneously inhibits the overexpression of BLyS and APRIL, effectively preventing abnormal differentiation and maturation of B cells [2] Group 3: Regulatory and Clinical Recognition - Taitasip has received multiple authoritative guideline recommendations in China, including the "Clinical Practice Guidelines for Sjögren's Syndrome" and the "Expert Consensus on B-cell Targeted Therapy for Rheumatic and Immune Diseases" [2] - Internationally, Taitasip has been granted Fast Track designation by the U.S. FDA for its indication in Sjögren's syndrome and has been approved to conduct global multi-center Phase III clinical trials [2]
恒生银行(00011.HK)8月14日回购2286.70万港元,已连续10日回购
Zheng Quan Shi Bao Wang· 2025-08-14 13:37
Core Viewpoint - Hang Seng Bank has been actively repurchasing its shares, indicating a strategy to support its stock price and enhance shareholder value [2] Summary by Category Share Buyback Activity - On August 14, Hang Seng Bank repurchased 200,000 shares at a price range of HKD 113.600 to HKD 115.400, totaling HKD 22.867 million [2] - Since August 1, the bank has conducted share buybacks for 10 consecutive days, acquiring a total of 2 million shares for a cumulative amount of HKD 228 million [2] - During this period, the stock price has increased by 0.34% despite the recent buyback activities [2] Stock Performance - The closing price of Hang Seng Bank on August 14 was HKD 113.700, reflecting a decrease of 0.87% for the day [2] - The total trading volume for the day was HKD 287 million [2] Detailed Buyback Data - The following table summarizes the buyback details for the past days: | Date | Shares Repurchased (thousand) | Highest Price (HKD) | Lowest Price (HKD) | Buyback Amount (thousand HKD) | |------------|-------------------------------|---------------------|--------------------|-------------------------------| | 2025.08.14 | 20.00 | 115.400 | 113.600 | 2286.70 | | 2025.08.13 | 20.00 | 115.800 | 114.400 | 2296.14 | | 2025.08.12 | 20.00 | 115.400 | 114.100 | 2300.02 | | 2025.08.11 | 20.00 | 116.200 | 115.100 | 2315.60 | | 2025.08.08 | 20.00 | 114.700 | 113.800 | 2286.94 | | 2025.08.07 | 20.00 | 115.100 | 113.200 | 2289.15 | | 2025.08.06 | 20.00 | 113.600 | 112.800 | 2263.47 | | 2025.08.05 | 20.00 | 114.200 | 113.100 | 2271.70 | | 2025.08.04 | 20.00 | 114.000 | 111.900 | 2267.19 | | 2025.08.01 | 20.00 | 114.300 | 112.400 | 2259.22 | [2]
恒生银行8月14日斥资2286.7万港元回购20万股
Zhi Tong Cai Jing· 2025-08-14 10:05
恒生银行(00011)发布公告,于2025年8月14日,该公司斥资2286.7万港元回购20万股。 ...
恒生银行(00011)8月14日斥资2286.7万港元回购20万股
Zhi Tong Cai Jing· 2025-08-14 10:04
智通财经APP讯,恒生银行(00011)发布公告,于2025年8月14日,该公司斥资2286.7万港元回购20万 股。 ...
恒生银行(00011.HK)8月14日耗资2286.7万港元回购20万股
Ge Long Hui· 2025-08-14 09:57
Group 1 - Hang Seng Bank announced a share buyback plan on August 14, 2025, involving an expenditure of HKD 22.867 million to repurchase 200,000 shares [1] - The buyback price range is set between HKD 113.6 and HKD 115.4 per share [1]
恒生银行(00011) - 翌日披露报表

2025-08-14 09:56
| 第一章節 | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | | 00011 | 說明 | 股份 | | | | | | | 多櫃檯證券代號 | | 80011 | RMB 說明 | 股份 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | | | 已發行股份(不包括庫存股份)變動 | | 庫存股份變動 | | | | | | 事件 | | 已發行股份(不包括庫存股份)數 目 | | 佔有關事件前的現有已發 行股份(不包括庫存股 份)數目百分比 (註3) | 庫存股份數目 | 每股發行/出售價 (註4) | 已發行股份總數 | | | 於下列日期開始時的結存(註1) | | 2025年8月13日 | | 1,882,267,536 | | 0 | | | 1,882,267,536 | | 1). 其 ...

